Format

Send to

Choose Destination
Clin Pharmacol Ther. 2018 Nov;104(5):966-973. doi: 10.1002/cpt.1023. Epub 2018 Feb 13.

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs.

Author information

1
Medicines Evaluation Board, Utrecht, the Netherlands.
2
Department of Epidemiology, CAPHRI, Maastricht University, the Netherlands.
3
Laboratory of Applied Pharmacokinetics and Bioinformatics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
4
Department of Pharmacy, Radboud University Medical Centre, Nijmegen, the Netherlands.
5
Department of Clinical Pharmacy and Toxicology, CARIM, Maastricht University, the Netherlands.

Abstract

Substitution by generic drugs is allowed when bioequivalence to the originator drug has been established. However, it is known that similarity in exposure may not be achieved at every occasion for all individual patients when switching between formulations. The ultimate aim of our research is to investigate if pharmacokinetic subpopulations exist when subjects are exposed to bioequivalent formulations. For that purpose, we developed a pharmacokinetic model for gabapentin, based on data from a previously conducted bioavailability study comparing gabapentin exposure following administration of the gabapentin originator and three generic gabapentin formulations in healthy subjects. Both internal and external validation confirmed that the optimal model for description of the gabapentin pharmacokinetics in this comparative bioavailability study was a two-compartment model with absorption constant, an absorption lag time, and clearance adjusted for renal function, in which each model parameter was separately estimated per administered formulation.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center